Imbruvica (ibrutinib) - AbbVie, J&J
Rituxan (rituximab) - Roche
cyclosporine - Generic mfg.
Clinical characteristics and prognosis of patients with direct antiglobulin test-negative autoimmune hemolytic anemia (PubMed, Zhonghua Xue Ye Xue Za Zhi) - Oct 10, 2026 - "Both patients who failed to respond to glucocorticoids achieved remission following salvage treatment with ibrutinib plus rituximab and cyclosporine plus rituximab. Relapses were mainly triggered by drug tapering (73.7%) and infection (21.1%) . After a comprehensive diagnostic workup to exclude other causes and immunoglobulin A (IgA) - or IgM-mediated AIHA, patients with DAT-negative AIHA generally have a relatively favorable prognosis and show good responses to glucocorticoids, rituximab, and other immunosuppressive therapies." 
Journal • Retrospective data • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology • Infectious Disease
http://www.ncbi.nlm.nih.gov/pubmed/42851175
 
F K Zhang; J A Zhang; J Shi; J W Qiu; M L Ge; X Zhao; Y Z Zheng
 
Oct 10, 2026
 
Prev Next